Core Viewpoint - BrainsWay Ltd. has completed an additional $6 million milestone-based convertible loan to Neurolief Ltd. following the FDA's Premarket Approval for Neurolief's ProlivRx system, which is aimed at enhancing patient access to innovative mental health treatments [1][2] Group 1: Investment and Strategic Partnership - BrainsWay has invested a total of $11 million in Neurolief to date, with potential for an additional $5 million equity investment based on Neurolief achieving specific revenue targets [4] - The strategic investment agreement includes a "call option" for BrainsWay to acquire all outstanding equity interests in Neurolief at a price determined by either a specified enterprise value or a revenue multiple [4] Group 2: Product Development and Market Expansion - Neurolief's ProlivRx is designed for treatment-resistant major depressive disorder (MDD) and has received FDA approval as an adjunctive treatment for adults who have not responded satisfactorily to previous antidepressant medications [5] - Neurolief has begun scaling its commercial operations and expanded provider access through inclusion in the Veterans Affairs Federal Supply Schedule, establishing a clear commercial pathway into the VA health system [3] Group 3: Company Profiles - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with its Deep TMS technology having three FDA-cleared indications [6] - Neurolief is focused on developing breakthrough therapies for mental health and neurological disorders, including the world's first wearable, non-invasive brain neuromodulation system [5]

Core Insights - SAGA Metals Corp. has acquired a 100% interest in the Garneau Project from Rio Tinto Exploration Canada Inc, which includes 120 claims over 6,450.54 hectares in Quebec, enhancing its portfolio in critical minerals [1][3][27] Project Highlights - The Garneau Project is located in a significant titanium-bearing district, near Rio Tinto's Lac Tio operation, known for its high-grade ilmenite deposits [3][4] - Initial grab samples from the project returned assays of 65.1% Fe₂O₃, 32.4% TiO₂, and 2,260 ppm vanadium, indicating strong mineralization potential [3][14][18] Geology and Infrastructure - The project is situated within the Havre-Saint-Pierre Anorthosite Complex, recognized for its magmatic iron-titanium oxide mineralization, which supports strong exploration potential [7][8] - Recent infrastructure developments, including the Romaine hydroelectric complex and a new access road, enhance the project's logistical advantages [4][25][26] Exploration and Development - Rio Tinto's previous work advanced the Garneau Project to a drill-ready stage, identifying a significant magnetic anomaly that suggests the presence of ilmenite-bearing systems [6][19] - The project is characterized by a large magnetic low measuring approximately 4.5 km by 7.5 km, which is considered highly prospective for further exploration [9][17] Acquisition Terms - The acquisition involved a termination agreement where RTEC assigned the Garneau Project to SAGA in lieu of incurring certain exploration expenditures [27] - SAGA has also agreed to a 2% Net Smelter Returns royalty on mineral extraction from the Garneau Project [32]

Core Insights - Plus Therapeutics, Inc. has appointed Ron Andrews, a veteran in the diagnostics industry, to its Board of Directors, which is expected to enhance the company's strategic direction and growth in the diagnostics sector, particularly for CNSide [1][2] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system, aiming to improve clinical outcomes [4] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery approaches [4] Leadership and Expertise - Ron Andrews brings over 35 years of experience in the diagnostics and molecular diagnostics industry, having held leadership roles in both large organizations and successful startups, and has been instrumental in raising over $600 million in capital and leading over $15 billion in exits [2] - His connections within the global diagnostics industry are expected to help Plus Therapeutics maximize the impact of its CNSide product on patients and drive shareholder value [2] Product Development - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary laboratory-developed tests, including CNSide, which identifies tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas [3] - The CNSide CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, improving the management of patients with leptomeningeal metastases [3]

Core Insights - Transglobal Management Group, Inc. (TMGI) is restructuring its leadership and Board of Directors to facilitate an uplisting to the OTCQB Market [1][2] Leadership Changes - Scott Carlston has been appointed as Chief Financial Officer, while Kelly Kirchhoff has been named Chief Executive Officer, aiming to enhance the company's public infrastructure and focus on golf operations [2] Operational Performance - Stand-By Golf is showing strong performance due to customer retention, expanding partnerships, and increased platform utilization, contributing positively to TMGI's overall strategy [3] Strategic Outlook - TMGI plans for Stand-By Golf to be central to its long-term growth strategy, focusing on strategic acquisitions and operational growth in golf, leisure, hospitality, and technology-enabled services [4] About Stand-By Golf - Stand-By Golf has over 37 years of operating history, offering golfers savings of 20% to 60% on tee times at over 200 championship-caliber courses in key markets [5] About GETGOLF, LLC - GETGOLF is a next-generation golf platform set to launch in Q3 2026, integrating real-time tee-time booking, travel planning, and social networking for golfers [6] Strategic Initiatives - The company aims to build scalable, technology-enabled platforms, expand predictable revenue streams, leverage synergies across its assets, and enhance customer acquisition and lifetime value [8]

Core Insights - Cognition Therapeutics is advancing the clinical development of zervimesine for treating psychosis associated with dementia with Lewy bodies (DLB), with a meeting with the FDA Division of Psychiatry expected by mid-2026 [1][2] Clinical Development - The company has developed a clinical plan for zervimesine, targeting a patient population with no approved treatment options for DLB psychosis [2] - The 545-patient 'START' trial in early Alzheimer's disease has completed enrollment, with results expected in 2027 to inform future development [2][7] - The company plans to advance zervimesine into late-stage trials for DLB psychosis based on strong efficacy signals observed in previous studies [10] Financial Results - As of December 31, 2025, the company reported cash and cash equivalents of approximately $37.0 million, with total obligated grant funds remaining at $35.7 million, indicating sufficient cash to fund operations through Q2 2027 [4] - Research and development expenses decreased to $37.2 million in 2025 from $41.7 million in 2024, attributed to the completion of clinical trials [5] - General and administrative expenses also decreased to $10.6 million in 2025 from $12.3 million in 2024, primarily due to reduced stock-based compensation [6] - The net loss for 2025 was $23.5 million, or $(0.32) per share, an improvement from a net loss of $34.0 million, or $(0.86) per share, in 2024 [6][15] Operational Highlights - The company launched an expanded access program for DLB patients and appointed Dr. David Weinstein as VP of clinical development [7] - A meeting with the FDA is planned to discuss the path forward for zervimesine in treating DLB psychosis [7] - The company has conducted an end-of-Phase 2 meeting with the FDA and received alignment on the development plan for zervimesine in Alzheimer's disease [7]

Core Insights - Bombardier has delivered the first Global 8000 aircraft to NetJets, marking a significant milestone in their partnership and the private aviation industry [2][4][5] - The Global 8000 features a range of 8,000 nautical miles (16.75 hours) and a top speed of Mach 0.95 (627 miles per hour), enhancing travel options and comfort for NetJets customers [2][5] - NetJets plans to build a fleet of 24 Global 8000 aircraft and will upgrade its existing Global 7500 fleet to the new model [3][5] Company Overview - Bombardier is recognized for designing, building, modifying, and maintaining high-performance aircraft, catering to discerning customers including businesses and governments [7][8] - The company operates a network supporting over 5,200 aircraft globally, with manufacturing facilities in Canada, the United States, and Mexico [9] Product Features - The Global 8000 is the only true four-zone business jet, allowing for nonstop travel between more city pairs than its competitors, with takeoff and landing performance akin to light jets [4][6] - The aircraft includes advanced features such as Bombardier's Pũr Air System and Soleil circadian lighting, aimed at maximizing passenger comfort and minimizing jet lag [6] Industry Context - NetJets, a Berkshire Hathaway company, has been a leader in private aviation for over 60 years, known for its commitment to safety and service [11] - The Global 8000 is positioned as a revolutionary aircraft in the business aviation landscape, offering unmatched performance and luxury [4][5]

Core Insights - Medicus Pharma Ltd. announced promising results from its Phase 2 SkinJect® study, indicating an overall response rate (ORR) of 80% in the 200µg cohort at Day 57, suggesting that the majority of treated lesions may avoid surgery [2][9] - The company aims to address a significant unmet medical need in non-melanoma skin cancer, particularly basal cell carcinoma (BCC), which is the most common cancer worldwide [7][18] Group 1: Clinical Data and Analysis - The 200µg cohort demonstrated a 73% clinical clearance rate at Day 57, indicating that approximately three out of four treated lesions may achieve visual resolution, potentially allowing many patients to defer or avoid immediate surgical intervention [8][11] - The study showed continued improvement in clearance rates from Day 29 to Day 57, supporting the notion of a durable treatment effect [12] - The dataset is considered decision-grade, supporting regulatory engagement and potential business partnerships [14] Group 2: Expert Insights and Perspectives - Dr. Babar Rao, a key opinion leader in dermatology, will provide an independent clinical interpretation of the dataset during the upcoming conference call, emphasizing the clinical significance of the findings in the context of the broader BCC treatment landscape [4][5] - The findings highlight a significant treatment backlog in BCC, where patients may face delays or undergo unnecessary procedures [5] Group 3: Strategic Positioning and Future Plans - The company is entering a catalyst-rich period, with plans to refine histological clearance endpoints and engage in discussions with the FDA regarding the registrational study design [14] - Medicus is also focusing on optimizing clinical trial design and exploring co-development opportunities, including a collaboration with Helix Nanotechnologies for mRNA vaccine development [19][20] - The company aims to position SkinJect as a minimally invasive alternative to surgery, addressing a large and underserved BCC patient population [14][18]

Core Insights - Wave Life Sciences announced significant results from the Phase 1 portion of the INLIGHT trial for WVE-007, showing notable reductions in visceral fat and waist circumference after a single 240 mg dose over six months [1][2][3] Group 1: Clinical Trial Results - A single 240 mg dose of WVE-007 resulted in a 14% reduction in visceral fat and a 3% reduction in waist circumference at the six-month follow-up, with a 2% increase in lean mass [1][4] - The Phase 1 trial included 32 participants with an average BMI of 32 kg/m, which is lower than the BMI of participants in later-stage obesity studies [3][4] - The visceral fat-to-muscle ratio improved by 16.5% compared to baseline, outperforming the 12.2% reduction seen with semaglutide in a higher BMI population [5] Group 2: Future Development Plans - The Phase 2a portion of the INLIGHT trial is set to begin in Q2 2026, targeting individuals with higher BMI (35-50 kg/m) and comorbidities, aiming for further body composition improvements [1][9][12] - The Phase 2a study will assess multiple parameters over a 12-month period, including body weight, waist circumference, and muscle function [9] Group 3: Safety and Tolerability - WVE-007 has been reported to be generally safe and well tolerated, with no severe treatment-emergent adverse events noted in the trial [7][11] - All treatment-related adverse events were mild, and there were no significant changes in clinical laboratory measurements [7] Group 4: Mechanism of Action - WVE-007 targets INHBE mRNA, leading to fat loss through lipolysis while preserving muscle mass, which is crucial for maintaining metabolic health [2][14] - A reduction in visceral fat of 5-10% is linked to a significantly lower risk of developing metabolic-associated fatty liver disease (MASH), type 2 diabetes, and cardiovascular disease [2][5]

Core Viewpoint - North American Niobium and Critical Minerals Corp. is set to begin its first diamond drilling program at the Seigneurie Project following the receipt of an Authorization for Impact-Causing Exploration Work (ATI) from Québec's Ministère des Ressources naturelles et des Forêts, aimed at exploring niobium and rare earth element potential [1][3][5] Group 1: Authorization and Engagement - The ATI authorization allows the company to conduct impact-causing exploration activities, including the construction of drill access trails and diamond drilling programs, valid for two years until March 22, 2028 [3] - The company completed stakeholder engagement with local communities, including the First Nation Council of the Essipit Innus and the Municipality of Longue-Rive, addressing logistical considerations and access routes [4] Group 2: Geological Context and Historical Data - The Seigneurie Project is located in the Grenville geological province, known for various rare earth element and critical mineral occurrences [6] - Historical exploration in the 1970s intersected significant pegmatite bodies, with reported intervals of approximately 50–70 meters, but did not assay for rare earth elements or niobium [7] - Recent geological interpretations suggest a pegmatite intrusion may exceed 300 meters in width and is open in all directions, supported by surface mapping and historical drill data [8][9] Group 3: Future Exploration Plans - The upcoming drilling program aims to test the scale, continuity, and mineralization potential of the interpreted pegmatite system [9] - The company intends to leverage the ATI authorization to advance its exploration strategy at the Seigneurie Project [5]

Core Insights - Hillman Solutions Corp. has been awarded the 2026 James A. Wuenker Growth Award by REDI Cincinnati for its commitment to redeveloping the Forest Fair Mall site [1][4] - The redevelopment project will involve constructing a 715,000-square-foot multipurpose facility in Forest Park, Ohio, consolidating several of Hillman's operations [2][3] - The project reflects Hillman's long-term commitment to the Cincinnati region and aims to enhance operational efficiency and collaboration [3][5] Company Overview - Hillman Solutions Corp. is a leading provider of hardware-related products and merchandising solutions, founded in 1964 and headquartered in Cincinnati [6] - The company serves retail, pro distribution, and industrial MRO customers, with a product portfolio exceeding 111,000 SKUs [6] - Hillman differentiates itself through a dedicated sales team of over 1,200 associates and strong global sourcing and supply chain capabilities [6] Economic Impact - The Growth Award recognizes projects that significantly strengthen the regional economy, with Hillman being one of four organizations selected from 17 reviewed projects [4] - The demolition of the former mall is nearly complete, with construction of the new facility expected to commence later this year [3] - The project is seen as a transformative commitment to the region, enhancing Hillman's legacy of excellence and innovation [5]